Category
ANGIOTENSIN RECEPTOR BLOCKERS AND NEPRILYSIN INHIBITORS
ANGIOTENSIN RECEPTOR BLOCKERS AND NEPRILYSIN INHIBITORS
Consistent
Purity
Global-Ready
Molecules
Advanced
Manufacturing
Scalable
Production
Partnership
Support
Sacubitril Valsartan API has been developed by ASANA Pharmaceutical as part of its advanced cardiovascular product line. Sacubitril Valsartan API, identified by CAS number 936623-90-4, is a dual-acting compound that combines a neprilysin inhibitor and an angiotensin receptor blocker, used in the treatment of chronic heart failure with reduced ejection fraction.
ASANA Pharmaceutical is focused on the development and manufacturing of advanced cardiovascular APIs such as Sacubitril Valsartan. With robust capabilities in fixed-dose combination synthesis and strict adherence to international quality standards, ASANA delivers APIs designed for next-generation heart failure treatment. Our operations span North America, Europe, and Asia, backed by modern infrastructure and reliable global compliance.
ASANA Pharmaceutical partners with innovators in cardiovascular care, combining formulation science, regulatory insight, and scalable production to meet evolving therapeutic needs. Sacubitril Valsartan [CAS No. 936623-90-4] is a dual-acting molecule combining angiotensin receptor blockade with neprilysin inhibition, and is widely used in the management of chronic heart failure with reduced ejection fraction. As demand for combination therapies increases worldwide, ASANA is committed to delivering:
Sacubitril Sodium API are available on public databases such as Wikipidia!